Eventide Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Eventide Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-377,000	Closed	-$2.17M	–	148
2017 Q3	$2.17M	Hold	377,000	–	–	0.12%	102
2017 Q2	$1.2M	Hold	377,000	–	–	0.07%	112
2017 Q1	$1.28M	Hold	377,000	–	–	0.08%	102
2016 Q4	$1.09M	Hold	377,000	–	–	0.07%	107
2016 Q3	$2.22M	Hold	377,000	–	–	0.14%	94
2016 Q2	$1.13M	Hold	377,000	–	–	0.07%	103
2016 Q1	$2.02M	Hold	377,000	–	–	0.11%	102
2015 Q4	$4.47M	Buy	377,000 +61,700	+20%	+$706K	0.22%	91
2015 Q3	$2.59M	Buy	315,300 +40,000	+15%	+$462K	0.15%	93
2015 Q2	$3.84M	Buy	275,300 +133,200	+94%	+$2.44M	0.21%	83
2015 Q1	$3.42M	Buy	142,100 +58,400	+70%	+$1.31M	0.26%	79
2014 Q4	$1.38M	Buy	83,700 +20,000	+31%	+$231K	0.15%	90
2014 Q3	$811K	Hold	63,700	–	–	0.11%	94
2014 Q2	$1.44M	Buy	+63,700	New	+$1.16M	0.2%	84

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Eventide Asset Management's DRNA Position: Q4 2017 in Review

Eventide Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2017, closing a stake of 377,000 shares — an estimated $2.17M sold.

Eventide Asset Management first reported a position in DRNA in Q2 2014 and held it in 14 quarters. The position peaked at $4.47M in Q4 2015. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2017.

Eventide Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Eventide Asset Management sold 377,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2017, an estimated $2.17M.
Eventide Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 14 quarters.
Eventide Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $4.47M in Q4 2015.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2017.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.